PL3218378T3 - Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych - Google Patents

Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych

Info

Publication number
PL3218378T3
PL3218378T3 PL15793834T PL15793834T PL3218378T3 PL 3218378 T3 PL3218378 T3 PL 3218378T3 PL 15793834 T PL15793834 T PL 15793834T PL 15793834 T PL15793834 T PL 15793834T PL 3218378 T3 PL3218378 T3 PL 3218378T3
Authority
PL
Poland
Prior art keywords
deaza
bicyclo
amino
protein kinase
kinase inhibitors
Prior art date
Application number
PL15793834T
Other languages
English (en)
Inventor
Laura BUFFA
Maria Menichincheri
Ilaria MOTTO
Francesca Quartieri
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of PL3218378T3 publication Critical patent/PL3218378T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15793834T 2014-11-14 2015-11-12 Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych PL3218378T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193197 2014-11-14
EP15793834.1A EP3218378B1 (en) 2014-11-14 2015-11-12 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
PCT/EP2015/076411 WO2016075224A1 (en) 2014-11-14 2015-11-12 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
PL3218378T3 true PL3218378T3 (pl) 2020-10-19

Family

ID=51904767

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15793834T PL3218378T3 (pl) 2014-11-14 2015-11-12 Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych

Country Status (13)

Country Link
US (1) US10221181B2 (pl)
EP (1) EP3218378B1 (pl)
JP (1) JP6421241B2 (pl)
KR (1) KR102562866B1 (pl)
CN (1) CN107108631B (pl)
AU (1) AU2015345054B2 (pl)
CA (1) CA2967125C (pl)
CL (1) CL2017001204A1 (pl)
EA (1) EA039885B1 (pl)
ES (1) ES2792036T3 (pl)
MX (1) MX382607B (pl)
PL (1) PL3218378T3 (pl)
WO (1) WO2016075224A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
ES2987501T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Métodos de tratamiento de cánceres pediátricos
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS63609B1 (sr) 2016-04-15 2022-10-31 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
EP3442980B1 (en) * 2016-04-15 2021-06-09 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
SI3612519T1 (sl) 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine
CN110891573A (zh) 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途
WO2018237134A1 (en) * 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) * 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
WO2020086503A1 (en) * 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN114585606A (zh) 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
WO2021041976A1 (en) * 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
EP4069369A4 (en) 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE
IL294214B2 (en) 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
PH12022553024A1 (en) 2020-05-08 2024-05-20 Halia Therapeutics Inc Inhibitors of nek7 kinase
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
JP2023541047A (ja) 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
CN119454695A (zh) * 2020-09-23 2025-02-18 上海润石医药科技有限公司 Csf1r激酶抑制剂及其用途
JP2024505890A (ja) 2021-01-26 2024-02-08 シュレーディンガー， インコーポレイテッド がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
CN122003418A (zh) 2023-09-11 2026-05-08 薛定谔公司 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284274T3 (es) 1998-06-17 2007-11-01 Ohio University Precipitador electrostatico con membrana.
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
HRP20090495T1 (hr) 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
ES2436877T3 (es) 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
GB0725103D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
PT2421879E (pt) 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
AU2010303567B2 (en) 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas

Also Published As

Publication number Publication date
MX2017006366A (es) 2018-02-01
ES2792036T3 (es) 2020-11-06
EA039885B1 (ru) 2022-03-23
KR102562866B1 (ko) 2023-08-04
CA2967125A1 (en) 2016-05-19
EP3218378A1 (en) 2017-09-20
JP2017533932A (ja) 2017-11-16
AU2015345054B2 (en) 2020-03-05
CN107108631A (zh) 2017-08-29
US20170327506A1 (en) 2017-11-16
CA2967125C (en) 2022-10-25
KR20170082637A (ko) 2017-07-14
MX382607B (es) 2025-03-13
AU2015345054A1 (en) 2017-06-29
CL2017001204A1 (es) 2017-12-29
WO2016075224A1 (en) 2016-05-19
CN107108631B (zh) 2020-06-16
US10221181B2 (en) 2019-03-05
EA201791018A1 (ru) 2018-03-30
EP3218378B1 (en) 2020-01-08
JP6421241B2 (ja) 2018-11-07

Similar Documents

Publication Publication Date Title
ZA201700115B (en) Aminopyridazinone compounds as protein kinase inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
EP3149008B8 (en) Certain protein kinase inhibitors
EP3131900A4 (en) Heterocyclic kinase inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL246140A0 (en) History of bicyclic heterocyclics as bromodomain repressors
SI3704118T1 (sl) Aminoimidazopiridazini kot kinazni inhibitorji
AP2016009661A0 (en) Quinolizinone derivatives as pi3k inhibitors
HRP20182064T1 (hr) Derivati tetrahidrokinolina kao inhibitori bromodomene
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
ZA201808238B (en) Certain protein kinase inhibitors
IL258438B (en) 2-Aminoquinoline derivatives as p70s6 kinase inhibitors
EP3186247A4 (en) Protein kinase inhibitors
IL252866A0 (en) History of imidazopyridazine as pi3kbeta inhibitors
EP3224248A4 (en) Certain protein kinase inhibitors
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
AU2014903812A0 (en) Novel kinase inhibitors i
TH1501006103A (th) สารยับยั้งโปรตีนไคเนส
AU2015904223A0 (en) Novel kinase inhibitors i
AU2015903106A0 (en) Novel kinase inhibitors ii
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors